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Abstract: Gold nanoparticles (GNPs) have gained significant interest as nanovectors for 
  combined imaging and photothermal therapy of tumors. Delivered systemically, GNPs 
  preferentially accumulate at the tumor site via the enhanced permeability and retention effect, 
and when irradiated with near infrared light, produce sufficient heat to treat tumor tissue. 
The efficacy of this process strongly depends on the targeting ability of the GNPs, which is a 
function of the particle’s geometric properties (eg, size) and dosing strategy (eg, number and 
amount of injections). The purpose of this study was to investigate the effect of GNP type and 
dosing strategy on in vivo tumor targeting. Specifically, we investigated the in vivo tumor-
targeting efficiency of pegylated gold nanoshells (GNSs) and gold nanorods (GNRs) for single 
and multiple dosing. We used Swiss nu/nu mice with a subcutaneous tumor xenograft model 
that received intravenous administration for a single and multiple doses of GNS and GNR. 
We performed neutron activation analysis to quantify the gold present in the tumor and liver. 
We performed histology to determine if there was acute toxicity as a result of multiple dosing. 
Neutron activation analysis results showed that the smaller GNRs accumulated in higher con-
centrations in the tumor compared to the larger GNSs. We observed a significant increase in 
GNS and GNR accumulation in the liver for higher doses. However, multiple doses increased 
targeting efficiency with minimal effect beyond three doses of GNPs. These results suggest a 
significant effect of particle type and multiple doses on increasing particle accumulation and 
on tumor targeting ability.
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Introduction
Nanovectors are increasingly being used as tumor-targeting agents for improved dis-
ease diagnosis and treatment strategies. Nanoparticles’ design, physical, and chemical 
  properties are central to achieving effective tumor targeting and consequently improv-
ing cancer diagnosis and treatment. In vivo tumor targeting using nanoparticles has 
primarily been achieved using a passive targeting mechanism known as enhanced 
permeability and retention (EPR).1 The tumors’ inherent leaky vasculature and inef-
fective lymph systems, enable systemically circulating nanoparticles to extravasate 
and accumulate in tumors due to the EPR effect.2 Recent efforts have focused on active 
targeting, which exploits the over-expression of surface receptors on cancer cells by 
providing targeting ligands that can engage these receptors.3–5 Choi et al demonstrated 
that targeted nanoparticles could provide greater intracellular delivery of therapeutic 
agents to the cancer cells within solid tumors than their nontargeted analogs.6 Although, 
there is continuous effort to identify suitable targeting moieties and ideal design 
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  parameters for active and passive targeting, respectively, little 
is known about the effect of nanoparticle dosing strategies 
on tumor targeting and accumulation capacity.
Multiple dosing is most commonly used in chemotherapy 
and radiation therapy for slowing and/or inhibiting tumor 
growth.7–9 Recently, Schluep et al demonstrated that a 
multiple dose of IT-101, a conjugate of camptothecin and 
a cyclodextrin-based polymer, showed increased antitumor 
activity in seven different mouse tumor xenografts.10 In 
addition, Herbst et al demonstrated high antitumor activity 
in patients with head and neck cancer using multiple doses 
of ZD1839 (gefinitib, an epidermal growth factor receptor 
tyrosine kinase inhibitor).11 In the present study, we investi-
gated the effect of a multiple dosing strategy using pegylated 
gold nanoparticles to increase the in vivo tumor targeting 
competence.
Pegylated gold nanoparticles (GNPs) are ideal for in 
vivo use as they are stable, non-toxic, and possess unique 
optical and thermal properties that make them effective con-
trast and photo-thermal agents.12,13 The polyethylene glycol 
(PEG) coating on the gold nanoparticles’ surface enables 
them to circulate longer and reduces nonspecific uptake 
by the reticuloendothelial system (RES).3 The RES, one of 
the body’s   filtration and defense mechanisms, functions to 
remove foreign particles and irregular red and white blood 
cells as well as opsonized particles.14 The liver and spleen 
that belong to the RES system are mainly responsible for 
the removal of different sized particles and hence these 
organs absorb a large percentage of systemically admin-
istered nanoparticles.15 Most of the biodistribution studies 
have shown that approximately 50%–60% of the injected 
dose of nanoparticles is taken up by the liver and spleen, 
respectively.16
Particles ranging from 10 nm to 15 µm in size have dif-
ferent biodistribution and pharmacokinetic parameters.17 
  Experiments from animal models suggest that sub-150 nm 
particles with neutral or slightly negatively charged entities 
can move through tumor tissue.18 Recent data show that sys-
temically delivered nanoparticles in the 50–100 nm size range 
that carry a very slight positive charge can penetrate through-
out large tumors.19 Therefore, nanoparticles in the 10–150 nm 
size range and with a neutral charge should have access to 
tumors when dosed into the circulatory system.20 Perrault 
et al have examined the particle size-dependent permeation 
of the tumor mass for the 20–100 nm size range and revealed 
a difference in behavior for different sizes, demonstrating 
that particle design has tremendous consequences on tumor 
targeting behavior.21
In this study, we investigated the effect of multiple dosing 
of GNPs and nanoparticle type to improve tumor-targeting 
efficiency. We utilized large pegylated gold nanoshells 
(GNSs) and small pegylated gold nanorods (GNRs) and 
compared the effect of the size of these particles on tumor 
targeting efficiency. Specifically, we compared the effect 
of single and multiple doses of GNRs and GNSs on in vivo 
tumor targeting. The choice of particles was driven by the 
ability of these particles to be photothermally activated. 
We used neutron activation analysis (NAA) to determine the 
amount of GNPs accumulated for the different doses and the 
percent accumulation of GNRs and GNSs in a squamous cell 
carcinoma tumor model. Our results indicated the efficacy 
of multiple dosing with increased accumulation of GNPs in 
tumors. Further, histopathological analysis of the tissues con-
firmed no acute toxicity due to multiple dosing. In addition, 
we studied the effect of particle type on tumor targeting and 
confirmed that smaller particles have enhanced accumulation 
in tumors compared to larger nanoparticles.
Materials and methods
Synthesis of pegylated gold  
nanoshells and gold nanorods
gNS synthesis
Nanoshells and nanorods used in this study were obtained 
from Nanospectra Biosciences Inc, (Houston, TX). The 
GNS fabrication is based on the method of Oldenburg.22 
Briefly, gold colloids, 1–3 nm in diameter, were grown over 
an aminated 120 ± 12 nm core of colloidal silica (Precision 
  Colloids, LLC, Cartersville, GA). Gold colloid and the 
particles were then further reacted with HAuCl4 in the pres-
ence of formaldehyde causing the gold surface to grow and 
coalesce, ultimately forming a complete shell. The gold sur-
face was then pegylated using thiolated polyethylene glycol 
(SH-PEG) (Laysan Bio, Huntsville, AL) to improve stability 
and blood circulation. GNS formation and dispersion in 
solution were assessed using a UV-Vis   spectrophotometer. 
A concentration of 2.66 × 109 (100× dilution factor) 
  particles/mL produced a peak OD of ∼1. The particles 
were designed to have a core size of 120 nm and a shell 
thickness of 15 nm resulting in a peak Plasmon resonance 
at 810 nm. For passive targeting, SH-PEG was added to 
the shell surface by combining 5 µM SH-PEG and GNS in 
deionized water for 12 hours, followed by diafiltration to 
remove the excess SH-PEG. The GNS were in 1 L volume, 
at a concentration of approximately 4 × 109 particles/mL. 
This corresponds to a particle concentration of ∼7 pM when 
5 µM PEG-SH is added.
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gNr synthesis
Nanorods were synthesized using the method developed 
by Jana et al.23 Briefly, gold seed particles were prepared 
by   adding 250 µL of 10 mM HAuCl4 3H2O to 7.5 mL of 
100 mM cetyltrimethylammonium bromide with brief, gentle 
mixing. Freshly prepared 600 µL of ice-cold 10 mM NaBH4 
solution was added and the solution was mixed for 2 minutes. 
The nanorod growth solution was prepared by adding 40 mL 
of 100 mM cetyltrimethylammonium bromide, 1.7 mL 
of 10 mM HAuCl4 ⋅ 3H2O, and 250 µL of 10 mM AgNO3 
followed by 270 µL of 100 mM ascorbic acid. To initiate 
nanorod growth, 840 µL of the seed solution was added to the 
growth solution, mixed gently, and left still for 40 minutes. 
Excess reactants were removed by centrifugation and resus-
pension in deionized (DI) water. For in vivo applications, 
the GNRs were pegylated by the addition of 1 mM thiol-
terminated methoxypolyethylene glycol (mPEG-SH) (Laysan 
Bio, Arab, AL) and the solution was stirred overnight. The 
final pegylated rod solution was cleaned by diafiltration of 
the solution into DI water. The synthesized GNRs had an 
aspect ratio of approximately 3.42 (GNR size: 24 × 7 nm). 
Both GNSs and GNRs were suspended in 10% trehalose 
because the particles exhibit greater long-term stability in 
trehalose compared to phosphate-buffered saline (PBS). In 
addition, 10% trehalose is iso-osmotic with blood. Figure 1 
illustrates the extinction spectrum of GNSs and GNRs used 
in this study.
Cell culture and tumor  
inoculation in mice
A431 cells (CRL-1555, human epithelial carcinoma 
cell line, American Type Culture Collection [ATCC], 
Manassas, VA) were grown in Dulbecco’s Modified 
Eagle’s medium (30-2002, ATCC) with 10% fetal bovine 
serum (30-2020, ATCC) at 37°C under 5% CO2. When 
culture reached 90% confluency, the cells were detached 
from the flask by 0.25% trypsin-EDTA (30-2101, ATCC), 
centrifuged, and resuspended in sterile PBS. Four- to six-
week old nude mice (Swiss nu/nu) were inoculated with 
the A431 cells.   Approximately 4 × 106 cells/50 µL were 
subcutaneously injected in the right thigh of 4- to 6-week-
old nude mice (Swiss nu/nu). When tumors attained a size 
of ∼ 8-10 mm in diameter, we performed intravenous delivery 
of nanoparticles.
gold nanoparticle dosing: single  
and multiple dosing
GNS and GNR solutions were intravenously injected via 
the mouse tail vein for single and multiple doses at 24-hour 
intervals. We systemically injected nanoparticles at 24 hour 
intervals since this time point has shown bulk nanoparticle 
clearance from blood allowing maximum particle accumula-
tion in tumors.2,24 We distributed 38 mice into six different 
groups. Table 1 shows the animal use for a range of doses 
and both particle types. Group 1 and 2 animals received 
7 µL/g of a single GNP dose (GNS: 2.74 × 108 particles/µL 
and GNR: 2.00 × 1011 particles/µL, optical density = 100) 
and were sacrificed after 24 hours followed by tumor and 
organ extraction for analysis. Groups 3 and 4 and Groups 5 
and 6 received multiple GNP doses once per day for 3 days 
and 5 days consecutively at 24-hour intervals, respectively. 
  Following the three and five GNP doses, animals were 
  sacrificed and the organs were extracted for analysis on days 
4 and 6, respectively. Our control group consisted of three 
mice that received intravenous administration of trehalose.
Neutron activation analysis (NAA)
We performed neutron activation analysis (NAA) to quan-
tify the amount of gold present in the extracted tumors and 
livers from the six mice groups. NAA is the gold standard 
method for trace gold quantification in biological samples, 
with sensitivities down to 70 pg.24 NAA was performed in 
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Figure 1 Extinction spectra of gNSs and gNrs.
Abbreviations: gNS, gold nanoshells; gNr, gold nanorods.
Table 1 Number of animals utilized in each dosing group for 
gNS and gNr injections
Particle  
type
Doses administered
1 3 5
gNS group 1 (n = 7) group 3 (n = 6) group 5 (n = 6)
gNr group 2 (n = 7) group 4 (n = 6) group 6 (n = 6)
Abbreviations: gNS, gold nanoshells; gNr, gold nanorods.
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the Nuclear Engineering Teaching Laboratory (NETL) at 
The University of Texas at Austin. Extracted tissues were 
weighed and placed inside the NAA vials. Following mass 
measurements, the vials containing tissue samples were 
placed in a desiccator and dehydrated for a week. Once 
desiccated, the vial lids were closed, and samples were sent 
to NETL for irradiation. From the amount of gold (mass 
of gold present in the samples) reported through NAA, 
and theoretical values for the mass of a single GNP, we 
calculated the number densities of GNSs and GNRs in the 
tumors and livers for all animal groups. The theoretically 
estimated mass of a single GNS (120 nm diameter core 
with 15 nm shell) and GNR (24 × 7 nm) were 1.33 × 10–8 µg 
and 1.61 × 10–11 µg (ρgold = 19.32 g/cm3). Additionally, to 
compare the percent-injected dose for GNS and GNR, the 
gold mass present in the injected samples (standards) were 
determined using NAA. Standards of GNSs and GNRs were 
prepared in NAA vials similar to the tissue preparation and 
were sent to NETL for irradiation. Based on the number of 
particles injected (reported from NAA of standards) and the 
number of particles accumulated in the tumors and livers 
(reported from NAA of tissue samples) for a single dose, 
we calculated the percent-injected dose per gram of tissue 
for GNSs and GNRs.
Histopathology
We performed histopathological analysis to determine if there 
was acute toxicity in tumors and in the RES organs (liver and 
spleen) for the mice groups that received the highest GNP 
dose (five doses). Liver, spleen and tumor from groups 5 and 
6 were examined by a pathologist at MD Anderson Cancer 
Center. The tissues from groups 1 and 2 (single dose) and 
the control group (trehalose injected) were also examined 
for comparison. In addition, we obtained light microscopy 
images of all the groups.
Results
Accumulation of gNSs and gNrs in 
tumor for single and multiple dosing
Figure 2 shows the accumulation of GNSs and GNRs in the 
tumor and liver for single, three and five doses based on NAA. 
These results show that three successive doses of GNPs lead 
to increased particle accumulation in the tumors.   Specifically, 
three consecutive doses resulted in approximately 2 and 
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Figure 2 (A and B) Number density of gNSs/g of tissue for different numbers of doses (1,3, and 5) in tumor and liver, respectively. (C and D) Number density of gNrs/g 
of tissue for different doses in tumor and liver, respectively. 
Notes: Error bars represent standard error. Brackets indicate statistical significance P , 0.05.
Abbreviations: gNS, gold nanoshells; gNr, gold nanorods.
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2.45 times increase in particle accumulation with GNSs and 
GNRs, respectively (Figure 2A and C). However, particle 
accumulation in tumors receiving five consecutive doses of 
GNPs via the tail vein was less than expected. We observed 
only a 3-fold increase with GNSs and 1.6-fold increase with 
GNRs in tumors for five doses. Note that the increase we refer 
to here is relative to a single dose. In summary, we observed 
an increase in the number densities of GNSs and GNRs in 
the tumor for higher doses (three and five doses) compared 
to a single dose (Figure 2A and C). Specifically, one versus 
three doses and one versus five doses were statistically sig-
nificant for both GNSs and GNRs. In the liver, which serves 
as a control, we observed a concomitant increase in number 
densities for GNSs with increase in doses: 3- and 4.6-fold 
increases for three and five doses, respectively (Figure 2B). 
However, for livers accumulated with GNRs, we observed 
an increase in number densities from single to three doses 
(3-fold increase) and a decrease from third to the fifth dose. 
However, this decrease/change was statistically insignificant. 
We also observed a similar, statistically insignificant decrease 
in the GNR tumor group.
Effect of particle type on tumor uptake
We observed a significant difference in tumor uptake of 
GNSs and GNRs for a single nanoparticle dose. Figure 3 
illustrates the fraction of GNSs and GNRs accumulated in 
tumor and liver for a known injected particle dose. In the 
tumor, the smaller pegylated GNRs showed approximately 
twelve times higher accumulation (1.35% ± 0.29% injected 
dose per gram of tissue [ID/g tissue]) compared to the 
larger pegylated GNSs (0.118% ± 0.027% ID/g tissue) after 
24 hours. Similarly, we observed 15 and 6 times increase in 
percent accumulation for GNRs compared to GNSs at 72- and 
120-hour time points, respectively (data not shown for 72 
and 120 hours). However, in the liver, there was no statistical 
difference in the percent accumulation of GNSs and GNRs 
(GNSs: 42% ± 2.11% ID/g tissue, GNRs: 37% ± 3.4% ID/g 
tissue) at 24 hours.
Histopathology of liver, spleen  
and tumor for multiple doses
We observed no signs of acute toxicity such as   sinusoidal 
dilation, inflammation or necrosis in the tumor, liver 
and spleen for multiple doses. Figure 4A–C show light 
microscopy images of tumor, liver and spleen stained with 
hematoxylin and eosin, respectively. The extent of typical 
inflammatory cell infiltration (lymphocytes and neutrophils) 
was similar in Group 1 tumors (single dose of GNSs and 
GNRs), Group 3 (five doses of GNSs and GNRs) and the 
control group (dose of trehalose). There were no significant 
differences in histopathological appearance observed in 
the livers (Figure 4B) and spleens (Figure 4C) between the 
groups. Furthermore, in the tumors, livers, and spleens ana-
lyzed, there was no histopathologically appreciable necrosis 
as a result of any presumed increase in microvascular block-
ade by aggregated GNPs, even in the group that received 
multiple doses of GNPs.
Discussion
In this study, we have shown that multiple dosing of gold 
nanoparticles injected systemically leads to a cumulative 
increase in particle accumulation in tumors. Multiple dosing 
is a common approach used in photodynamic, chemo and 
radiation therapies to treat tumors. In addition, multiple dosing 
has been shown to protract tumor growth in mouse models. In 
a recent study, mice bearing subcutaneous Neuro2A tumors 
were treated by intravenous injection with siRNA-containing 
nanoparticles formed with cyclodextrin-containing polyca-
tions (CDP). Three consecutive daily doses of transferrin 
(Tf)-targeted nanoparticles carrying two different siRNA 
sequences targeting ribonucleotide reductase subunit M2 
(RRM2) led to slow tumor growth.25 The nanoparticles used 
in our present study are known to be effective in vivo tumor 
targeting agents.2,26 In addition, their strong NIR plasmon 
peak (Figure 1) enables them to scatter, absorb or luminesce 
when excited in the NIR.27,28 Recently, we demonstrated 
that systemically delivered GNSs passively accumulated in 
human colon tumors and served as excellent absorption-based 
contrast agents for wide-field tumor imaging.29
Smaller particles have high permeation/diffusion through 
tumor interstitium and correspondingly, higher clearance 
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to surrounding normal tissue (where they are likely to be 
cleared).30 Jain et al and Boucher et al have shown that the 
interstitial fluid pressure decreases from the tumor core to 
the periphery and surrounding tissue, carrying nanoparticles 
with it by convection into the normal tissue as a function of 
particle size.31,32 This phenomenon could explain the decrease 
in smaller nanoparticle accumulation in tumors with days 
as noted in Figure 2C (decreasing trend in GNR number 
density observed in tumors from three to five doses). In 
contrast, larger particles have restricted and slow migration 
to the tumor environment along with slow clearance from 
the tumor owing to increased tumor accumulation with 
time.21,32 This explains the increase in GNS number density 
with increasing doses (more time to accumulate slowly) as 
seen in Figure 2A. However, a detailed study of the changes 
in nanoparticle accumulation in tumors for an extended time 
after single versus multiple dose delivery will help under-
stand the mechanisms of uptake and clearance for various 
nanoparticle types.
We analyzed the livers of mice that received single and 
multiple dosing of both GNPs, since the liver has exhibited 
significantly higher nanoparticle accumulation compared 
to other RES organs.14 Although the liver and spleen are 
the main organs of the RES responsible for the removal of 
nanoparticles, the percentage accumulation in the liver is 
significantly higher compared to other organs such as the 
spleen, kidney, and brain.24 In addition, since the overall goal 
of the project did not encompass nanoparticle biodistribution 
throughout the body, we elected to process only the tumor 
and liver samples from all mice. The statistically significant 
increase in tumor accumulation of GNPs with increasing 
dose number in the liver (Figure 2B) validates the multiple 
dosing approach. However, we noticed an interesting trend in 
the GNR group. There was a drop-off in GNR accumulation 
from the three-dose group to the five-dose group (Figure 2D). 
Although uptake of particles from blood to liver may occur 
relatively quickly, excretion of these particles from the liver 
is relatively slow, often resulting in prolonged retention of 
GNPs.33 The decrease in GNR number density in the liver 
for the five-dose group, albeit statistically insignificant, is 
intriguing and warrants further investigation. A complete 
biodistribution study would definitely provide a better 
understanding of nanoparticle accumulation and clearance 
at higher doses.
Nanoparticles’ size and half-life plays an important role 
in tumor accumulation of particles for diagnostic and thera-
peutic purposes. Perrault et al have shown that accumulation 
of smaller particles (less than 40 nm) in tumors is a function 
of both size and half-life. For particles larger than 40 nm, the 
accumulation is primarily a function of half-life.21 We used 
GNRs with a size of 24 × 7 nm having an approximate half-
life between 4–8 hours and GNSs of 135 nm diameter with 
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Figure 4 Light microscopy images of H&E stained tumor, liver and spleen from mice that received five doses of GNSs and GNRs and a dose of trehalose (control).
Abbreviations: gNS, gold nanoshells; gNr, gold nanorods; H&E, hematoxylin and eosin.
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an approximate half-life of 3 hours.2,24 The longer   half-life 
and smaller size of GNRs explains their nearly 12-fold higher 
accumulation compared to the larger GNS.
With both particle types examined in this study, the high-
est tumor accumulation as a fraction of GNPs injected was 
only about 2 (% ID/g). Hobbs et al have demonstrated that 
the vascular permeability and effective interstitial   diffusion 
  coefficient of a nanoparticle depends on the tumor type as 
well.34 The relatively low accumulation fraction of both 
pegylated GNRs and GNSs could be attributed to the tumor 
type as well. Pore cutoff sizes have been measured for a 
limited number of tumor models with the smallest reported 
at 100–200 nm.34 To our knowledge, the pore cutoff size for 
the squamous cell carcinoma tumors (A431 tumors) used in 
this study has not yet been reported. The size of the GNPs 
did not affect the accumulation in livers as observed in 
Figure 3B. This correlates well with prior research showing 
that nanoparticle accumulation in the liver was independent 
of particle size.14 However, as noted in an earlier paragraph, 
the GNRs appear to clear much faster from the liver after 
3 days.
Multiple dosing strategies did not lead to acute toxicity in 
mice during the course of the study. After administration of 
GNPs, mice were monitored daily for survival and behavior 
changes. There was no effect of multiple dose administrations 
of GNPs on mortality and behavioral impairment. There were 
no appreciable histopathological signs of acute toxicity such 
as inflammation, edema, sinusoidal dilation and necrosis 
in all mice groups. Further studies are required to ascertain 
the effect of multiple dosing on long-term clearance, safety 
and   biodistribution. Although we have shown the effect of 
multiple dosing using passive targeting of pegylated GNPs, 
future work could include multiple dosing of actively targeted 
  nanoparticles. Multiple dosing could potentially enhance imag-
ing contrast and also improve thermal therapy efficacy.
Conclusion
We have demonstrated the safety and efficacy of a multiple 
dosing approach using GNPs and found it to increase par-
ticle accumulation in tumor. NAA data demonstrates that 
multiple dosing caused higher particle accumulation in 
tumors compared to a single dose. We did not notice any signs 
of acute toxicity in the tumor, liver or spleen with multiple 
doses of GNPs. We have shown that particle type affects 
tumor accumulation as well as clearance; smaller nanorods 
accumulated more within tumors than the larger nanoshells. 
These results suggest that multiple dosing might be an effec-
tive method to increase GNP accumulation in tumors.
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